A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes

Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which prevent incretin degradation, have become popular oral hypoglycemic agents. The efficacy of DPP-4 inhibitors varies from individuals, and factors determining responses to DPP-...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Eugene, Park, Hye Sun, Kwon, Obin, Choe, Eun Yeong, Wang, Hye Jin, Lee, Yong-ho, Lee, Sang-Hak, Kim, Chul Hoon, Kim, Lee-Kyung, Kwak, Soo Heon, Park, Kyong Soo, Kim, Chul Sik, Kang, Eun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591096/
https://www.ncbi.nlm.nih.gov/pubmed/27858848
http://dx.doi.org/10.1097/MD.0000000000005155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591096/
https://www.ncbi.nlm.nih.gov/pubmed/27858848
http://dx.doi.org/10.1097/MD.0000000000005155

Ejemplares similares